Viral Resistance in Hepatitis B: Prevalence and Management
Open Access
- 6 February 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Current Gastroenterology Reports
- Vol. 12 (1), 62-69
- https://doi.org/10.1007/s11894-009-0088-1
Abstract
Hepatitis B is a DNA virus affecting hundreds of millions of individuals worldwide. As the clinical sequelae of cirrhosis and hepatocellular cancer are increasingly recognized to be related to viral levels, the impetus increases to offer treatment to those previously not treated. With the development of more robust antivirals with reasonable safety profiles, long-term treatment is becoming more common. The oral nucleos(t)ide analogs have become the preferred first-line therapies for most genotypes of hepatitis B. Five are now available, all with different potencies and resistance profiles. Long-term data spanning several years are now available for most compounds in this arena. This article focuses on the common natural variants and those secondary to nucleos(t)ide therapy, as well as diagnostic methods to detect resistance.Keywords
This publication has 25 references indexed in Scilit:
- Chronic hepatitis B: Update 2009Hepatology, 2009
- Ultra‐Deep Pyrosequencing of Hepatitis B Virus Quasispecies from Nucleoside and Nucleotide Reverse‐Transcriptase Inhibitor (NRTI)–Treated Patients and NRTI‐Naive PatientsThe Journal of Infectious Diseases, 2009
- Next-generation DNA sequencingNature Biotechnology, 2008
- Entecavir at Five Years Shows Long-Term Maintenance of High Genetic Barrier to Hepatitis B Virus ResistanceZeitschrift für Gastroenterologie, 2008
- Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular CarcinomaJNCI Journal of the National Cancer Institute, 2008
- Low Resistance to Adefovir Combined With Lamivudine: A 3-Year Study of 145 Lamivudine-Resistant Hepatitis B PatientsGastroenterology, 2007
- Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 YearsGastroenterology, 2006
- In Vitro Models for Studying Hepatitis B Virus Drug ResistanceSeminars in Liver Disease, 2006
- Antiviral Drug Resistance: Clinical Consequences and Molecular AspectsSeminars in Liver Disease, 2006
- Disruption of the function of tumor-suppressor gene p53 by the hepatitis B virus X protein and hepatocarcinogenesisZeitschrift für Krebsforschung und Klinische Onkologie, 1995